<DOC>
	<DOC>NCT01782222</DOC>
	<brief_summary>This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.</brief_summary>
	<brief_title>Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Patients with early or advanced idiopathic Parkinson's Disease Patients with advanced idiopathic Parkinson's Disease: intake of Levodopa on a stable dose of at least 200 mg/day Unsatisfactory control of Parkinson's Disease motor symptoms under current treatment Patients experiencing Apathy associated with Parkinson's Disease Hoehn and Yahr stage score of I to IV MiniMental State Examination score ≥ 25 If an antidepressant drug is taken, the dose must be stable Therapy with a Dopamine agonist Discontinuation from pervious therapy with a dopamine agonist after an adequate length of treatment, at adequate dose, due to lack of efficacy Any medical or psychiatric condition that jeopardizes / compromises patient's ability for participation Patient has received Neuroleptics, Dopamine releasing substances, Dopamine modulating substances, AlphaMethyldopa, Metoclopramide, MAOA inhibitors, Budipine, or Tolcapone Electroconvulsive therapy Patient has a current/anticipated psychotherapy or behavior therapy history of deep brain stimulation history of suicide attempt or has suicidal ideation impulse control disorder severe Depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>Rotigotine</keyword>
	<keyword>Apathy</keyword>
	<keyword>Nonmotor</keyword>
	<keyword>Motor</keyword>
	<keyword>Neupro</keyword>
</DOC>